Huiya Wu

Huiya Wu, a partner in Goodwin’s IP Litigation practice, is a member of the firm’s Life Sciences Disputes group and is an intellectual property litigator who has spent more than 25 years litigating and trying cases in both federal and state courts, and has appeared before the Patent and Trademark Office (PTO), the Patent Trial and Appeal Board (PTAB), as well as the International Trade Commission (ITC).  She has represented clients in a wide range of technologies, including pharmaceuticals, analytical devices, medical devices, automotive parts, and internet business methods, and has particular expertise in litigation under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act.

Huiya has been recognized in Intellectual Asset Management’s Patent 1000, an annual listing of the world’s leading patent practitioners, in which clients have described her as “super-clever, highly persuasive and thoughtful,” “a top-notch advocate and trusted adviser who helps you achieve your key business objectives,” and having “first-rate technical expertise and an appealing and effective courtroom presentation manner,” and “an excellent attorney who can always be trusted to put her clients’ needs first.”

She has an active pro bono practice, including her work with the Legal Services NYC, National Women’s Law Center, Project Citizenship, and is a recipient of the New York City Bar Association’s Thurgood Marshall Award for her work defending individuals in capital punishment cases. She also currently serves as co-chair of Goodwin’s Women’s Initiative.

Highlights of Huiya’s work includes representing or advising:

• University of Pittsburgh a currently pending patent infringement and breach of contract case involving muscle-derived stem cells.  University of Pittsburgh of the Commonwealth System of Higher Education v. Cook Myosite, Inc. (W.D.Pa.)  
• Zealand Pharma in a currently pending trade secret case involving a peptide-based therapeutic for complement-mediated diseases.  Amyndas Pharmaceuticals Single Member P.C. et al v. Alexion Pharmaceuticals, Inc. et al. (D. Mass.)  
• United Therapeutics as trial counsel in a patent infringement case involving an inhaled pharmaceutical product.  United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del.)  
• Amneal Pharmaceuticals in patent matters involving its biosimilars of Avastin and Neulasta as well as its generic vasopressin and dimethyl fumarate products.
• Biocon Biologics Ltd. on patent matters relating to its $3 billion acquisition of Viatris Inc.’s global biosimilars business.  
• Celltrion, Inc. in patent matters involving its biosimilars of Actemra, Herceptin, Humira,  and Rituxan.
• Harman Connected Services in a trade secret case involving dashcam with artificial intelligence capabilities.  Pritchard v. Thompson et al. (W.D. Tenn.)  
• Sun Pharmaceutical as lead trial counsel in a patent infringement case involving a generic drug product to treat rosacea.  Galderma et al. v. Sun Pharmaceutical et al. (D. Del.)
• Taro Pharmaceuticals in parallel patent infringement and inter partes review proceedings involving a generic drug product used to treat iron overload caused by blood transfusions.  ApoPharma et al. v. Taro Pharmaceuticals et al. (E.D. Tex./PTAB)
• Cipla, in a patent infringement case involving eye drops to treat ocular itching associated with allergies.  Alcon Research et al. v. Cipla Limited et al. (S.D. Ind.)
• Tris Pharma in a trade secret case involving a prescription cough syrup.  UCB Manufacturing v. Tris Pharma et al. (New Jersey state court)
• Robert Bosch in a patent infringement case before the ITC related to windshield wipers. In the Matter of Certain Wiper Blades (ITC)
• Boston Scientific at trial and on appeal in a patent infringement case related to stents. Cordis Corp. v. Boston Scientific Corp. et al. (D. Del.)
• Applied Biosystems at trial and on appeal in a patent infringement case related to mass spectrometers resulting in a jury verdict of $47.5 million.  AppliedBiosystems et al. v. Micromass UK Ltd. et al. (D. Del.)

Huiya is a member of the New York State Bar Association, the New York Intellectual Property Law Association, and the American Intellectual Property Law Association.

Huiya has been recognized by Patexia’s Top ANDA Litigators in 2020 list.

Huiya was named by IAM Patent 1000 – The World’s Leading Patent Professionals as one of the world’s leading patent litigators, 2016 - 2020.

In 2023, Huiya was recognized among Lawyers of Color's inaugural Wonderful Women, which recognizes dynamic women attorneys working in law firms, companies, and government agencies who show promise in their careers and demonstrate a strong commitment to advancing diversity in the legal profession.

• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2023-2024 ed.,” published by Thomson Reuters, January 2024
• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” published by Thomson Reuters, December 2022
• Speaker, “China Pharma: Strategies to Decrease Risk from Third-Party IP,” U.S.-China Intellectual Property Exchange and Development Foundation, April 2021
• Speaker, “US vs China: Goodwin Attorneys Discuss Patent Hurdles and Adalimumab Marketing,” The Center for Biosimilars, February 2021
• Speaker, “An Overview of the Biosimilars Market in China,” Goodwin Webinar, January 2021
• Speaker, “China’s Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?,” Goodwin Webinar (December 2020
• Speaker, “Top of Mind Issues for Global Life Sciences Companies in the Era of COVID-19,” Goodwin Webinar, April 2020
• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, November 2019
• Speaker, “What To Expect in U.S. Litigation on Biosimilars: A Comparison of the BPCIA and the Hatch-Waxman Act,” Webinar, August 2019